DOCSLIB.ORG

ENSG Gene Encodes Effector TCR Pathway Costimulation Inhibitory/Exhaustion Synapse/Adhesion Chemokines/Receptors

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

  • ENSG
  • Gene
  • Encodes
  • Effector
  • TCR pathway Costimulation Inhibitory/exhaustion Synapse/adhesion Chemokines/receptors

ENSG00000111537 IFNG ENSG00000109471 IL2
IFNg IL-2 TNFa CCL5 Klrg1 Fas ligand TRAIL Klrc1 / NKG2A Klrk1 / NKG2D PD-1 xxxxxxxxxxxx
ENSG00000232810 TNF ENSG00000271503 CCL5 ENSG00000139187 KLRG1 ENSG00000117560 FASLG ENSG00000121858 TNFSF10 ENSG00000134545 KLRC1 ENSG00000213809 KLRK1 ENSG00000188389 PDCD1 ENSG00000117281 CD160 ENSG00000134460 IL2RA xx

  • x
  • CD160

IL-2 receptor subunit alpha IL-10 receptor subunit alpha IL-18 receptor 1 IL-18 receptor accessory protein IL-12 receptor beta 2

  • ENSG00000110324 IL10RA
  • x

ENSG00000115604 IL18R1 ENSG00000115607 IL18RAP xx

  • ENSG00000081985 IL12RB2
  • x

ENSG00000186810 CXCR3 ENSG00000005844 ITGAL ENSG00000160255 ITGB2
CXCR3 CD11a CD18; Integrin beta-2 xxxxx
ENSG00000156886 ITGAD ENSG00000140678 ITGAX;
Integrin
CD11d CD11c x

  • x
  • x

xalpha-X

  • ENSG00000115232 ITGA4
  • CD49d; Integrin

alpha-4 x

  • ENSG00000169896 ITGAM
  • CD11b; Integrin

alpha-M

  • x
  • x

ENSG00000138378 STAT4 ENSG00000115415 STAT1 ENSG00000170581 STAT2 ENSG00000126561 STAT5a ENSG00000162434 JAK1 ENSG00000100453 GZMB ENSG00000145649 GZMA ENSG00000180644 PRF1 ENSG00000115523 GNLY ENSG00000100450 GZMH ENSG00000113088 GZMK ENSG00000057657 PRDM1 ENSG00000073861 TBX21 ENSG00000115738 ID2
Stat4 Stat1 Stat2 Stat5a xxxxxxxxxxxxxxxx
Jak1 Granzyme B Granzyme A Perforin 1 Granulysin Granzyme H Granzyme K Blimp-1 T-bet ID2 Hobit Interferon regulatory factor 4
ENSG00000176083 ZNF683 ENSG00000137265 IRF4

  • ENSG00000140968 IRF8
  • Interferon

regulatory factor 8Eomesodermin CCL4; MIP-1alpha CD27 CD28 CCR7 CCR2 CCR5 x

  • x
  • ENSG00000163508 EOMES

ENSG00000275302 CCL4 ENSG00000139193 CD27 ENSG00000178562 CD28 ENSG00000126353 CCR7 ENSG00000121807 CCR2 ENSG00000160791 CCR5 ENSG00000171791 BCL2 xxxxxxxx
Bcl2
ENSG00000081059 TCF7 ENSG00000182866 LCK ENSG00000115085 ZAP70 ENSG00000213658 LAT
Tcf1 Lck ZAP70 Linker for activation of T cells xxxxx

  • ENSG00000010810 FYN
  • Fyn

GrB2 MAPK14 Growth factor receptor bound protein 2 xxxx
ENSG00000107968 MAP3K8 ENSG00000006062 MAPK14

  • ENSG00000177885 GRB2
  • x

xx

  • ENSG00000082701 GSK3B
  • Glycogen

synthase kinase 3 beta Itk Fos Jun JunB Kras Ras homolog family member A NFATC1 NFATC2 NFATC3 NFATC4 NFKB1 x
ENSG00000113263 ITK ENSG00000170345 FOS ENSG00000177606 JUN ENSG00000171223 JUNB ENSG00000133703 KRAS ENSG00000067560 RHOA xxxxxx

ENSG00000131196 NFATC1 ENSG00000101096 NFATC2 ENSG00000072736 NFATC3 ENSG00000100968 NFATC4 ENSG00000109320 NFKB1 ENSG00000100906 NFKBIA xxxxx

  • x
  • NFKB inhibitor

alpha

  • ENSG00000104825 NFKBIB
  • NFKB inhibitor

beta x
ENSG00000146232 NFKBIE ENSG00000070831 CDC42
NFKB inhibitor epsilon Cell division control protein 42 homolog x

  • x
  • x

ENSG00000167286 CD3D ENSG00000198851 CD3E ENSG00000160654 CD3G ENSG00000121879 PIK3CA
CD3 delta chain CD3 epsilon chain CD3 gamma chain PI3K alpha subunit xxx

  • x
  • x

ENSG00000051382 PIK3CB ENSG00000171608 PIK3CD ENSG00000105851 PIK3CG
PI3K beta subunit PI3K delta subunit PI3K gamma subunit xxx

ENSG00000149269 PAK1 ENSG00000077264 PAK3 ENSG00000137843 PAK6 ENSG00000100030 MAPK1 ENSG00000102882 MAPK3 ENSG00000185386 MAPK11 ENSG00000050748 MAPK9 ENSG00000156711 MAPK13 ENSG00000169032 MAP2K1 ENSG00000126934 MAP2K2 ENSG00000076984 MAP2K7 ENSG00000115904 SOS1 ENSG00000100485 SOS2 ENSG00000158092 NCK1
PAK-1 PAK-3 PAK-6 xxxxxxxxxxxxxx
MAPK1 MAPK3 MAPK11 MAPK9 MAPK13 MAP2K1 MAP2K2 MAP2K7 Sos-1 Sos-2 NCK adaptor protein 1

  • ENSG00000071051 NCK2
  • NCK adaptor

protein 2 x
ENSG00000142208 AKT1 ENSG00000105221 AKT2
Protein kinase B Protein kinase B beta xxxx

ENSG00000117020 AKT3 ENSG00000135446 CDK4 ENSG00000139318 DUSP6
Protein kinase B gamma Cyclin-dependent kinase 4 Dual Specificity Phosphatase 6 LIGHT OX40 receptor Icos 4-1BB HVEM GITR GRB2-related adaptor protein PI3K regulatory subunit 1 xxxx
ENSG00000125735 TNFSF14 ENSG00000117586 TNFSF4 ENSG00000163600 ICOS ENSG00000049249 TNFRSF9 ENSG00000157873 TNFRSF14 ENSG00000186891 TNFRSF18 ENSG00000100351 GRAP2 xxxxxxx

  • ENSG00000145675 PIK3R1
  • x

ENSG00000179295 PTPN11 ENSG00000152256 PDK1

  • Ptpn11
  • x

  • x
  • Pyruvate

dehydrogenase kinase 1
ENSG00000089692 LAG3 ENSG00000122223 CD244 ENSG00000163599 CTLA4 ENSG00000198846 TOX ENSG00000181847 TIGIT ENSG00000119772 DNMT3A

  • LAG3
  • x

xxxxx
CD244 CTLA-4 Tox Tigit DNA methyltransferase 3 alpha

  • ENSG00000153094 BCL2L11
  • Bcl2 like 11
  • x

  • ENSG00000156127 BATF
  • Basic leucine

zipper ATF-like transcription factor x
ENSG00000091972 CD200 ENSG00000163606 CD200R1 ENSG00000186265 BTLA ENSG00000135077 HAVCR2 ENSG00000141968 VAV1 ENSG00000160293 VAV2 ENSG00000134215 VAV3 ENSG00000149294 NCAM1 ENSG00000090339 ICAM1 ENSG00000131323 TRAF3 ENSG00000111737 RAB35
CD200 CD200 receptor 1 BTLA Tim-3 Vav1 xxxxxxxxxxx
Vav2 Vav3 NCAM-1 ICAM-1 TRAF3 Ras-related protein Rab-35 Ras-related protein Rab-22a Ras guanylreleasing protein 2
ENSG00000124209 RAB22A ENSG00000068831 RASGRP2 xx

  • ENSG00000077549 CAPZB
  • F-actin-capping

protein subunit beta x
ENSG00000196924 FLNA ENSG00000130429 ARPC1B
Filamin-A Actin-related protein 2/3 xx

complex subunit 1B

  • ENSG00000120318 ARAP3
  • Arf-GAP with Rho-

GAP domain, ANK repeat and PH- xdomain containing protein 3
ENSG00000184922 FMNL1

ENSG00000070182 SPTB ENSG00000157827 FMNL2 ENSG00000109920 FNBP4 ENSG00000220205 VAMP2
Formin-like protein 1 Spectrin beta chain Formin-like protein 2 Formin-binding protein 4 xxxx

  • x
  • Vesicle-associated

membrane protein 2
ENSG00000099331 MYO9B ENSG00000006125 AP2B1

  • Myosin IXB
  • x

  • x
  • AP-2 complex

sbunit beta PAK4 Integrin alpha5 Integrin beta-3 Integrin alpha-IIb Myosin-9 Myosin-10 Beta-actin CD14
ENSG00000130669 PAK4 ENSG00000161638 ITGA5 ENSG00000259207 ITGB3 ENSG00000005961 ITGA2B ENSG00000100345 MYH9 ENSG00000133026 MYH10 ENSG00000075624 ACTB ENSG00000170458 CD14 ENSG00000108622 ICAM2 ENSG00000163947 ARHGEF3 xxxxxxxxxx
ICAM-2 Rho guanine nucleotide exchange factor 3 Myosin light chain 5

  • ENSG00000215375 MYL5
  • x

ENSG00000162704 ARPC5 ENSG00000136950 ARPC5L ENSG00000241553 ARPC4 ENSG00000111229 ARPC3
Actin-related protein 2/3 complex subunit 5Actin-related protein 2/3 complex subunit 5-like protein Actin-related protein 2/3 complex subunit 4xxx

  • x
  • Actin-related

protein 2/3 complex subunit 3
ENSG00000242498 ARPIN ENSG00000070087 PFN2 ENSG00000128340 RAC2
Arpin Profilin-2 Ras-related C3 botulinum toxin substrate 2 xxx

  • ENSG00000129675 ARHGEF6
  • Rho guanine

nucleotide exchange factor 6 xxx
ENSG00000198752 CDC42BPB CDC42-binding protein kinase beta Rho guanine nucleotide
ENSG00000131089 ARHGEF9 exchange factor 9
ENSG00000179604 CDC42EP4 CDC42 effector protein 4 x

  • x
  • ENSG00000170962 PDGFD
  • Platelet-derived

growth factor D
ENSG00000174775 HRAS ENSG00000072110 ACTN1 ENSG00000077522 ACTN2 ENSG00000130402 ACTN4 ENSG00000172725 CORO1B ENSG00000175203 DCTN2

  • GTPase Hras
  • x

xxxxx
Alpha-actinin-1 Alpha-actinin-2 Alpha-actinin-4 Coronin-1B Dynactin subunit 2
ENSG00000132912 DCTN4

ENSG00000104671 DCTN6 ENSG00000166847 DCTN5
Dynactin subunit 4Dynactin subunit 6Dynactin subunit 5xxx
ENSG00000277632 CCL3 ENSG00000143184 XCL1 ENSG00000143185 XCL2 ENSG00000169245 CXCL10 ENSG00000169429 CXCL8 ENSG00000108702 CCL1 ENSG00000102970 CCL17 ENSG00000275385 CCL18 ENSG00000172724 CCL19 ENSG00000137077 CCL21 ENSG00000102962 CCL22 ENSG00000274736 CCL23 ENSG00000163739 CXCL1 ENSG00000138755 CXCL9 ENSG00000169248 CXCL11 ENSG00000107562 CXCL12 ENSG00000161921 CXCL16 ENSG00000121966 CXCR4
MIP1beta XCL1 XCL2 CXCL10 IL-8; CXCL8 CCL1 CCL17 CCL18 CCL19 CCL21 CCL22 CCL23 CXCL1 CXCL9 CXCL11 CXCL12 CXCL16 CXCR4 xxxxxxxxxxxxxxxxxx
ENSG00000160683 CXCR5 ENSG00000163823 CCR1 ENSG00000183625 CCR3 ENSG00000183813 CCR4 ENSG00000112486 CCR6 ENSG00000179934 CCR8 ENSG00000173585 CCR9 ENSG00000184451 CCR10 ENSG00000168329 CX3CR1 ENSG00000172215 CXCR6
CXCR5 CCR1 CCR3 CCR4 CCR6 CCR8 CCR9 CCR10 CX3CR1 CXCR6 xxxxxxxxxxx

Recommended publications
  • Screening and Identification of Key Biomarkers in Clear Cell Renal Cell Carcinoma Based on Bioinformatics Analysis

    Screening and Identification of Key Biomarkers in Clear Cell Renal Cell Carcinoma Based on Bioinformatics Analysis

    bioRxiv preprint doi: https://doi.org/10.1101/2020.12.21.423889; this version posted December 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Screening and identification of key biomarkers in clear cell renal cell carcinoma based on bioinformatics analysis Basavaraj Vastrad1, Chanabasayya Vastrad*2 , Iranna Kotturshetti 1. Department of Biochemistry, Basaveshwar College of Pharmacy, Gadag, Karnataka 582103, India. 2. Biostatistics and Bioinformatics, Chanabasava Nilaya, Bharthinagar, Dharwad 580001, Karanataka, India. 3. Department of Ayurveda, Rajiv Gandhi Education Society`s Ayurvedic Medical College, Ron, Karnataka 562209, India. * Chanabasayya Vastrad [email protected] Ph: +919480073398 Chanabasava Nilaya, Bharthinagar, Dharwad 580001 , Karanataka, India bioRxiv preprint doi: https://doi.org/10.1101/2020.12.21.423889; this version posted December 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Clear cell renal cell carcinoma (ccRCC) is one of the most common types of malignancy of the urinary system. The pathogenesis and effective diagnosis of ccRCC have become popular topics for research in the previous decade. In the current study, an integrated bioinformatics analysis was performed to identify core genes associated in ccRCC. An expression dataset (GSE105261) was downloaded from the Gene Expression Omnibus database, and included 26 ccRCC and 9 normal kideny samples. Assessment of the microarray dataset led to the recognition of differentially expressed genes (DEGs), which was subsequently used for pathway and gene ontology (GO) enrichment analysis.
  • Cd160 Mouse Shrna Plasmid (Locus ID 54215) – TR514223 | Origene

    Cd160 Mouse Shrna Plasmid (Locus ID 54215) – TR514223 | Origene

    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for TR514223 Cd160 Mouse shRNA Plasmid (Locus ID 54215) Product data: Product Type: shRNA Plasmids Product Name: Cd160 Mouse shRNA Plasmid (Locus ID 54215) Locus ID: 54215 Synonyms: AU045688; By55 Vector: pRS (TR20003) Format: Retroviral plasmids Components: Cd160 - Mouse, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 54215). 5µg purified plasmid DNA per construct Non-effective 29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free. RefSeq: BC021596, NM_001163496, NM_001163497, NM_018767 Summary: CD160 antigen: Receptor on immune cells capable to deliver stimulatory or inhibitory signals that regulate cell activation and differentiation. Exists as a GPI-anchored and as a transmembrane form, each likely initiating distinct signaling pathways via phosphoinositol 3- kinase in activated NK cells and via LCK and CD247/CD3 zeta chain in activated T cells (By similarity). Receptor for both classical and non-classical MHC class I molecules (PubMed:16177084). Receptor or ligand for TNF superfamily member TNFRSF14, participating in bidirectional cell-cell contact signaling between antigen presenting cells and lymphocytes. Upon ligation of TNFRSF14, provides stimulatory signal to NK cells enhancing IFNG production and anti-tumor immune response (PubMed:25711213). On activated CD4+ T cells, interacts with TNFRSF14 and downregulates CD28 costimulatory signaling, restricting memory and alloantigen-specific immune response (By similarity). In the context of bacterial infection, acts as a ligand for TNFRSF14 on epithelial cells, triggering the production of antimicrobial proteins and proinflammatory cytokines (PubMed:22801499).[UniProtKB/Swiss-Prot Function] shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus.
  • PFN2, a Novel Marker of Unfavorable Prognosis, Is a Potential Therapeutic

    PFN2, a Novel Marker of Unfavorable Prognosis, Is a Potential Therapeutic

    Cui et al. J Transl Med (2016) 14:137 DOI 10.1186/s12967-016-0884-y Journal of Translational Medicine RESEARCH Open Access PFN2, a novel marker of unfavorable prognosis, is a potential therapeutic target involved in esophageal squamous cell carcinoma Xiao‑bin Cui1,2†, Shu‑mao Zhang1†, Yue‑xun Xu3, Hong‑wei Dang1, Chun‑xia Liu1, Liang‑hai Wang1, Lan Yang1, Jian‑ming Hu1, Wei‑hua Liang1, Jin‑fang Jiang1, Na Li4, Yong Li5*, Yun‑zhao Chen1* and Feng Li1,2* Abstract Background: Esophageal squamous cell carcinoma (ESCC) is one of the most aggressively malignant tumors with dismal prognosis. Profilin 2 (PFN2) is an actin-binding protein that regulates the dynamics of actin polymerization and plays a key role in cell motility. Recently, PFN2 have emerged as significant regulators of cancer processes. However, the clinical significance and biological function of PFN2 in ESCC remain unclear. Methods: PFN2 protein expression was validated by immunohistochemistry (IHC) on tissue microarray from Chinese Han and Kazakh populations with ESCC. The associations among PFN2 expression, clinicopathological features, and prognosis of ESCC were analyzed. The effects on cell proliferation, invasion and migration were examined using MTT and Transwell assays. Markers of epithelial–mesenchymal transition (EMT) were detected by Western blot analysis. Results: Compared with normal esophageal epithelium (NEE), PFN2 protein expression was markedly increased in low-grade intraepithelial neoplasia (LGIN), high-grade intraepithelial neoplasia (HGIN), and ESCC, increased gradually from LGIN to ESCC, and finally reached high grade in HGIN in the Han population. Similarly, PFN2 protein was more overexpressed in ESCC than in NEE in the Kazakh population.
  • Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse

    Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse

    Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only.
  • 3034.Full.Pdf

    3034.Full.Pdf

    Characterization of the CD200 Receptor Family in Mice and Humans and Their Interactions with CD200 This information is current as Gavin J. Wright, Holly Cherwinski, Mildred Foster-Cuevas, of September 28, 2021. Gary Brooke, Michael J. Puklavec, Mike Bigler, Yaoli Song, Maria Jenmalm, Dan Gorman, Terri McClanahan, Man-Ru Liu, Marion H. Brown, Jonathon D. Sedgwick, Joseph H. Phillips and A. Neil Barclay J Immunol 2003; 171:3034-3046; ; Downloaded from doi: 10.4049/jimmunol.171.6.3034 http://www.jimmunol.org/content/171/6/3034 References This article cites 39 articles, 20 of which you can access for free at: http://www.jimmunol.org/ http://www.jimmunol.org/content/171/6/3034.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 28, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2003 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Characterization of the CD200 Receptor Family in Mice and Humans and Their Interactions with CD2001 Gavin J.
  • A1068-CD86 Polyclonal Antibody

    A1068-CD86 Polyclonal Antibody

    BioVision 05/16 For research use only CD86 Polyclonal Antibody CATALOG NO: A1068-100 ALTERNATIVE NAMES: T-lymphocyte activation antigen CD86, Activation B7-2 antigen, B70, BU63, CTLA-4 counter-receptor B72, FUN-1, CD86, CD86, CD28LG2 Western blot analysis of CD86 in NCI-H292 cell line lysate AMOUNT: 100 µl IMMUNOGEN: KLH conjugated synthetic peptide between 269-298 amino acids from the C-terminal region of human CD86. MOLECULAR WEIGHT: 37 kDa HOST/ISOTYPE: Rabbit IgG SPECIES REACTIVITY: Human PURIFICATION: This antibody is purified through a protein A column, followed by peptide affinity purification. FORM: Liquid FORMULATION: Supplied in PBS with 0.09% (W/V) sodium azide. STORAGE CONDITIONS: Maintain refrigerated at 2-8°C for up to 6 months. For long term RELATED PRODUCTS storage store at -20°C in small aliquots to prevent freeze-thaw cycles. DESCRIPTION: This gene encodes a type I membrane protein that is a member of the immunoglobulin superfamily. This protein is expressed by Human CellExp™ B7-2 /CD86, human recombinant (Cat. No. 7496-10, -50) antigen-presenting cells, and it is the ligand for two proteins at the CD86 (Human) ELISA Kit (Cat. No. K4175-100) cell surface of T cells, CD28 antigen and cytotoxic T-lymphocyte- Human CellExp™LAG3 /CD223, human recombinant (Cat. No. 7278-10, -50) associated protein 4. Binding of this protein with CD28 antigen is a costimulatory signal for activation of the T-cell. Binding of this CD223 (LAG3) Polyclonal Antibody (Cat. No. A1067-100) protein with cytotoxic T-lymphocyte-associated protein 4 negatively regulates T-cell activation and diminishes the immune response.
  • Decreased Expression of Profilin 2 in Oral Squamous Cell Carcinoma and Its Clinicopathological Implications

    Decreased Expression of Profilin 2 in Oral Squamous Cell Carcinoma and Its Clinicopathological Implications

    ONCOLOGY REPORTS 26: 813-823, 2011 Decreased expression of profilin 2 in oral squamous cell carcinoma and its clinicopathological implications C.Y. MA1,2, C.P. ZHANG1,2, L.P. ZHONG1,2, H.Y. PAN1,2, W.T. CHEN1,2, L.Z. WANG3, O.W. ANDREW4, T. JI1 and W. HAN1,2 1Department of Oral and Maxillofacial Surgery, Ninth People's Hospital, College of Stomatology; 2Shanghai Key Laboratory of Stomatology and Shanghai Research Institute of Stomatology; 3Department of Oral Pathology, Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, P.R. China; 4Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, National University of Singapore, Singapore 119074, Singapore Received February 8, 2011; Accepted April 11, 2011 DOI: 10.3892/or.2011.1365 Abstract. Profilins are small proteins essential for many clinical and pathological significance. In conclusion, PFN2 normal cellular dynamics and constitute one of the crucial can be utilized as both a potential suppressor marker and a components of actin-based cellular motility. Several recent prognostic protein for OSCC. The function of PFN2 may be to studies have implicated a role for the profilin (PFN) family in regulate the N-WASP/Arp2/3 signaling pathway. cancer pathogenesis and progression. However, their expression and promising functions are largely unknown in oral squamous Introduction cell carcinoma (OSCC). In this study, we analyzed the correlation between PFN1 and PFN2 expression in vitro and Oral squamous cell carcinoma (OSCC) is a significant public in vivo. The protein expression levels were roughly compared health problem with >300,000 new cases being diagnosed between cell lines (HIOEC, HB96) with the employment of annually worldwide (1).
  • The CAP-Gly and Basic Microtubule Binding Domains of Dynactin Are

    The CAP-Gly and Basic Microtubule Binding Domains of Dynactin Are

    Knockdown of dynactin’s p150Glued subunit abrogates microtubule organization by Jared Todd Roeckner A Thesis Submitted to the Faculty of The Wilkes Honors College In Partial Fulfillment of the Requirements for the Degree of Bachelor of Arts in Liberal Arts and Sciences with a Concentration in Biology Wilkes Honors College of Florida Atlantic University Jupiter, Florida May 2009 Knockdown of dynactin’s p150Glued subunit abrogates microtubule organization by Jared T. Roeckner This thesis was prepared under the direction of the candidate’s thesis advisor, Dr. Nicholas Quintyne, and has been approved by the members of the supervisory committee. It was submitted to the faculty of The Honors College and was accepted in partial fulfillment of the Requirements for the Degree of Bachelor of Arts in Liberal Arts and Sciences. SUPERVISORY COMMITTEE: ________________________ Dr. Nicholas Quintyne ________________________ Dr. Paul Kirchman ________________________ Dean, Wilkes Honors College _________ Date ii ACKNOWLEDGEMENTS First, I would like to thank Dr. Nicholas Quintyne for allowing me to work in his lab for the last three years and overseeing and guiding my thesis research and writing. I would like to acknowledge Dr. Stephen King and Dr. Margret Kincaid at UMKC for providing us with the p150Glued knockdown plasmids. Dr. Paul Kirchman, April Mistrik, and everyone in the Quintyne lab helped me out greatly. Ed Fulton and I worked on many steps of this project together and I thank him for his help. Finally, I would like to thank my family and friends for supporting of my thesis research and my undergraduate studies as a whole. iii ABSTRACT Author: Jared Todd Roeckner Title: Knockdown of dynactin’s p150Glued subunit abrogates microtubule organization Institutions: Harriet L.
  • Tools for Cell Therapy and Immunoregulation

    Tools for Cell Therapy and Immunoregulation

    RnDSy-lu-2945 Tools for Cell Therapy and Immunoregulation Target Cell TIM-4 SLAM/CD150 BTNL8 PD-L2/B7-DC B7-H1/PD-L1 (Human) Unknown PD-1 B7-1/CD80 TIM-1 SLAM/CD150 Receptor TIM Family SLAM Family Butyrophilins B7/CD28 Families T Cell Multiple Co-Signaling Molecules Co-stimulatory Co-inhibitory Ig Superfamily Regulate T Cell Activation Target Cell T Cell Target Cell T Cell B7-1/CD80 B7-H1/PD-L1 T cell activation requires two signals: 1) recognition of the antigenic peptide/ B7-1/CD80 B7-2/CD86 CTLA-4 major histocompatibility complex (MHC) by the T cell receptor (TCR) and 2) CD28 antigen-independent co-stimulation induced by interactions between B7-2/CD86 B7-H1/PD-L1 B7-1/CD80 co-signaling molecules expressed on target cells, such as antigen-presenting PD-L2/B7-DC PD-1 ICOS cells (APCs), and their T cell-expressed receptors. Engagement of the TCR in B7-H2/ICOS L 2Ig B7-H3 (Mouse) the absence of this second co-stimulatory signal typically results in T cell B7-H1/PD-L1 B7/CD28 Families 4Ig B7-H3 (Human) anergy or apoptosis. In addition, T cell activation can be negatively regulated Unknown Receptors by co-inhibitory molecules present on APCs. Therefore, integration of the 2Ig B7-H3 Unknown B7-H4 (Mouse) Receptors signals transduced by co-stimulatory and co-inhibitory molecules following TCR B7-H5 4Ig B7-H3 engagement directs the outcome and magnitude of a T cell response Unknown Ligand (Human) B7-H5 including the enhancement or suppression of T cell proliferation, B7-H7 Unknown Receptor differentiation, and/or cytokine secretion.
  • Molecular and Clinical Characterization of LAG3 in Breast Cancer Through 2994 Samples

    Molecular and Clinical Characterization of LAG3 in Breast Cancer Through 2994 Samples

    Molecular and Clinical Characterization of LAG3 in Breast Cancer Through 2994 Samples Qiang Liu Chinese Academy of Medical Sciences & Peking Union Medical College Yihang Qi ( [email protected] ) Chinese Academy of Medical Sciences and Peking Union Medical College https://orcid.org/0000-0001- 7589-0333 Jie Zhai Chinese Academy of Medical Sciences & Peking Union Medical College Xiangyi Kong Chinese Academy of Medical Sciences & Peking Union Medical College Xiangyu Wang Chinese Academy of Medical Sciences & Peking Union Medical College Yi Fang Chinese Academy of Medical Sciences & Peking Union Medical College Jing Wang Chinese Academy of Medical Sciences & Peking Union Medical College Research Keywords: Cancer immunotherapy, CD223, LAG3, Immune response, Inammatory activity Posted Date: June 19th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-36422/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/33 Abstract Background Despite the promising impact of cancer immunotherapy targeting CTLA4 and PD1/PDL1, a large number of cancer patients fail to respond. LAG3 (Lymphocyte Activating 3), also named CD233, is a protein Coding gene served as alternative inhibitory receptors to be targeted in the clinic. The impact of LAG3 on immune cell populations and co-regulation of immune response in breast cancer remained largely unknown. Methods To characterize the role of LAG3 in breast cancer, we investigated transcriptome data and associated clinical information derived from a total of 2994 breast cancer patients. Results We observed that LAG3 was closely correlated with major molecular and clinical characteristics, and was more likely to be enriched in higher malignant subtype, suggesting LAG3 was a potential biomarker of triple-negative breast cancer.
  • SUPPLEMENTARY DATA Supplementary Tables Table S1

    SUPPLEMENTARY DATA Supplementary Tables Table S1

    1 SUPPLEMENTARY DATA 2 3 Supplementary Tables 4 Table S1. Gene signatures Gene signature Genes Cytolytic GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 Cytotoxic CD8+ T cells CD8A, GZMA, GZMB, IFNG, EOMES, PRF1 Activated CD4+ T cells CD4, IL2RA, CD69 CD4+ Treg cells FOXP3, CTLA4, ICOS Immune checkpoints—T cells BTLA, LAG3, HAVCR2, PDCD1, TIGIT, CTLA4 T cells CD2, CD3D, CD3E, CD3G, CD6, TRAT1, CD28, LCK B cells CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, FCRL5 NK cells SLAMF7, KLRC3, KLRK1, KLRC2, KLRD1 Monocytes CD14, CD16, CD163, CSF1R, HLA-DR LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, M2 macrophages PTPRC, SLA, SEPSECS, MSR1, FPR3, FCGR2A, FCGR3A, IDO1, RERE, ABL2, CD163L1, STAT3, SBNO2, CSF1, CSF2 FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL12a1, Active fibroblasts COL5A1, COL8A2, THY1, PALLD Antigen processing TAPBP, TAP1, TAP2, PSMB9, PSMB8 Immune checkpoints—APC CD274, PDCD1LG2, IDO1 Costimulatory ligands CD40, CD80, CD86, CD70, TNFRSF18 CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, Costimulatory receptors TNFSF14, CD226 Myeloid inflammation CCL2, IL1B, CXCL8, IL6, PTGS2 1 DERL1, DERL2, DNAJB11, DNAJB9, DNAJC10, DNAJC3, ER stress EDEM1, EDEM2, EDEM3, EIF2AK3, ERO1L, HERPUD1, PDIA3, PDIA6, SEC61A1, SERP1, SYVN1 RRM2, UBE2C, BIRC5, CEP55, CCNB1, NUF2, NDC80, Proliferation MKI67, CDC20, TYMS 5 ER, endoplasmic reticulum; NK, natural killer. 6 7 2 8 Table S2. Most common all-cause and treatment-related AEs Patients (N = 45) All cause Treatment related Eventa Any grade Grade 3/4 Any grade Grade 3/4 Any AE 45 (100.0) 20 (44.4)
  • Overview of the Cytoskeleton from an Evolutionary Perspective

    Overview of the Cytoskeleton from an Evolutionary Perspective

    Downloaded from http://cshperspectives.cshlp.org/ on October 1, 2021 - Published by Cold Spring Harbor Laboratory Press Overview of the Cytoskeleton from an Evolutionary Perspective Thomas D. Pollard1 and Robert D. Goldman2 1Departments of Molecular Cellular and Developmental Biology, Molecular Biophysics and Biochemistry, and Cell Biology ,Yale University, New Haven, Connecticut 06520-8103 2Department of Cell and Molecular Biology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611 Correspondence: [email protected] SUMMARY Organisms in the three domains of life depend on protein polymers to form a cytoskeleton that helps to establish their shapes, maintain their mechanical integrity, divide, and, in many cases, move. Eukaryotes have the most complex cytoskeletons, comprising three cytoskeletal poly- mers—actin filaments, intermediate filaments, and microtubules—acted on by three families of motor proteins (myosin, kinesin, and dynein). Prokaryotes have polymers of proteins ho- mologous to actin and tubulin but no motors, and a few bacteria have a protein related to intermediate filament proteins. Outline 1 Introduction—Overview of cellular 4 Overview of the evolution of the cytoskeleton functions 5 Conclusion 2 Structures of the cytoskeletal polymers References 3 Assembly of cytoskeletal polymers Editors: Thomas D. Pollard and Robert D. Goldman Additional Perspectives on The Cytoskeleton available at www.cshperspectives.org Copyright # 2018 Cold Spring Harbor Laboratory Press; all rights reserved; doi: 10.1101/cshperspect.a030288 Cite this article as Cold Spring Harb Perspect Biol 2018;10:a030288 1 Downloaded from http://cshperspectives.cshlp.org/ on October 1, 2021 - Published by Cold Spring Harbor Laboratory Press T.D. Pollard and R.D. Goldman 1 INTRODUCTION—OVERVIEW OF CELLULAR contrast, intermediate filaments do not serve as tracks for FUNCTIONS molecular motors (reviewed by Herrmann and Aebi 2016) but, rather, are transported by these motors.